9 Things Doctors Still Get Wrong About Perimenopause in 2024
The number of women who've been told 'you're too young' or 'your bloods are normal' when they were deep in perimenopause is staggering — and honestly, infuriating. That dismissal doesn't just delay treatment; it makes women doubt their own bodies at exactly the moment they need to trust them most. This one is worth reading with a pen in hand.
Learn more about Rose →Perimenopause Only Lasts a Year or Two
The average duration of perimenopause is four to eight years, and for some women it stretches to a decade. Research published in journals including JAMA Internal Medicine has confirmed that the transition begins years before the final menstrual period, often in the early-to-mid forties. Women told to 'wait it out' on this basis may spend most of their forties in an undertreated hormonal transition.
Your Hormones Must Be 'Low' on a Blood Test Before Treatment Is Warranted
FSH and estradiol levels during perimenopause fluctuate dramatically — sometimes day to day — making a single snapshot blood test an unreliable diagnostic tool. The Menopause Society and NICE guidelines both state that perimenopause is a clinical diagnosis in women over 45, meaning symptoms alone are sufficient to guide treatment decisions. Sending a woman away because her FSH was normal on a Tuesday misses the entire point of how this transition works.
Hot Flushes Are the Defining Symptom — If You Don't Have Them, It Probably Isn't Perimenopause
While vasomotor symptoms like hot flushes affect roughly 75% of women, the other 25% experience perimenopause primarily through mood changes, sleep disruption, joint pain, cognitive symptoms, or cycle irregularity. Anchoring diagnosis to hot flushes alone means a significant minority of women are never identified or offered support. The symptom picture is far broader than most clinical training reflects.
The Women's Health Initiative Proved HRT Is Dangerous
The 2002 WHI study caused decades of harm by being widely misrepresented — its participants had an average age of 63, were largely obese, and were given oral conjugated equine estrogen combined with a synthetic progestogen not used in modern practice. Subsequent reanalysis, along with the work of researchers like Dr. JoAnn Manson who led parts of the WHI itself, has clarified that for healthy women under 60 or within ten years of menopause, the benefit-to-risk ratio of hormone therapy is favourable. The 'HRT causes breast cancer' headline that followed that study is still being repeated in consulting rooms today, despite the evidence having moved on substantially.
Anxiety and Depression in Perimenopause Are a Mental Health Problem, Not a Hormonal One
The perimenopausal brain undergoes measurable neurological changes as estrogen — a key modulator of serotonin, dopamine, and GABA — becomes erratic. Studies using neuroimaging have shown altered brain activity during this transition, and longitudinal research confirms that women with no prior history of depression face a significantly elevated risk during perimenopause specifically. Treating this with SSRIs alone, without addressing the underlying hormonal driver, is like treating a thyroid disorder with therapy.
Irregular Periods Are the First Sign That Perimenopause Has Started
For many women, hormonal symptoms — including worsening PMS, sleep disruption, mood shifts, and brain fog — precede any cycle irregularity by two to four years. This phase is sometimes called 'early perimenopause' and is driven by progesterone decline before estrogen begins to fluctuate significantly. Women whose cycles are still regular are sometimes dismissed as 'not in perimenopause yet,' even when they are symptomatic and would benefit from support.
Genitourinary Symptoms Will Resolve on Their Own After Menopause
Unlike vasomotor symptoms, which often improve with time, genitourinary syndrome of menopause (GSM) — which includes vaginal dryness, urinary urgency, recurrent UTIs, and painful sex — tends to worsen progressively without treatment. This is because the tissues of the vulva, vagina, and lower urinary tract are highly estrogen-dependent, and without intervention they undergo atrophy that compounds over years. Local vaginal estrogen is safe, effective, and carries essentially no systemic absorption risk, yet many women are still told to 'use a lubricant and see how it goes.'
Women With a History of Breast Cancer Cannot Use Any Form of Hormone Therapy
While systemic HRT remains a nuanced and individualised conversation for breast cancer survivors, local vaginal estrogen — used to treat GSM — has extremely minimal systemic absorption and is considered low-risk by most oncology guidelines, including those from ASCO. Blanket refusals to discuss any hormonal option for women with a cancer history leave many suffering from severe genitourinary symptoms that significantly affect quality of life. These women deserve an informed, individualised discussion rather than a categorical no.
If Symptoms Are Manageable, Treatment Isn't Necessary
Perimenopause is not only a symptomatic event — it is a physiological transition with long-term implications for bone density, cardiovascular health, and cognitive function. Estrogen plays a protective role in all three systems, and the years immediately following menopause represent a window of opportunity when hormone therapy has its strongest evidence for reducing long-term disease risk. A woman who is 'coping' with symptoms but not thriving may still be accumulating silent health risks that are worth a frank conversation with a clinician who understands the full picture.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.